Welcome to our dedicated page for Scienture Holdings news (Ticker: SCNX), a resource for investors and traders seeking the latest updates and insights on Scienture Holdings stock.
Scienture Holdings, Inc. (NASDAQ: SCNX) generates news that centers on specialty pharmaceutical product launches, commercialization milestones, financing activities and corporate governance developments. Through its wholly owned subsidiary Scienture, LLC, the company focuses on novel specialty products that address unmet market needs, and its announcements frequently highlight progress in bringing these therapies to patients, physicians and healthcare institutions.
Recent Scienture news has emphasized Arbli™, which the company describes as the first and only oral liquid formulation of losartan approved by the U.S. FDA and the first FDA-approved, ready-to-use oral suspension formulation of losartan potassium. Updates have covered the start of commercial sales and fulfillment of initial orders, availability of Arbli™ through full-line wholesalers nationwide, multiple group purchasing organization (GPO) agreements providing access to thousands of healthcare institutions, and the addition of Arbli™ to formularies of major national health plans.
Another major news theme is REZENOPY™ (naloxone HCl) Nasal Spray 10 mg, which Scienture presents as the highest dosage naloxone HCl nasal spray approved by the FDA for emergency treatment of known or suspected opioid overdose. Company releases have described exclusive U.S. commercialization rights, FDA approval, and the issuance of an Orange Book-listable U.S. patent that may support the product’s U.S. commercialization.
Investors following SCNX news can also expect updates on SEC filings, equity distribution arrangements, secured financing transactions, conversion of prior debentures into common stock, and notices related to Nasdaq listing requirements. Governance and shareholder matters, such as annual meeting proposals, equity incentive plan amendments and bylaw changes, are reported through both press releases and current reports on Form 8-K. This news feed offers a centralized view of Scienture’s commercial progress, regulatory developments and capital markets activity.
Scienture Holdings (NASDAQ: SCNX) has transformed from a health services IT company to a specialty pharmaceutical company through strategic moves in 2024-2025. The company completed a $22.5M sale of TRXaDE Inc. assets and merged with Scienture Inc. in a $103M all-stock transaction.
The company now has two FDA-approved commercial products scheduled for launch in H2 2025: ArbliTM (in-house developed) and REZENOPY® (acquired in March 2025). The company's pipeline includes multiple products under development:
- SCN-104: Injectable pen for migraine treatment
- SCN-106: CVS therapeutic biosimilar
- SCN-107: Non-opioid post-surgical pain management
REZENOPY®, a 10mg naloxone HCl nasal spray, targets a market with annual sales of $189M. The combined market opportunity for their two commercial products is $481M, based on IQVIA data (December 2024).
SCIENTURE HOLDINGS (NASDAQ: SCNX) has announced two significant developments in its commercial operations. First, Michele Rath has been appointed as Senior Vice President and Chief Commercial Officer (CCO) of Scienture, , effective November 1, 2024. Rath brings over 20 years of industry experience from previous roles at Pfizer, CVS Caremark, and Aurobindo Pharma.
Second, the company has established a strategic partnership with Syneos Health Commercial Services through a Master Commercial Services Agreement (MCSA). Syneos Health will serve as Scienture's Contract Sales Organization, providing field sales, inside sales, and customer engagement services supported by their Kinetic platform analytics.
These developments aim to support the upcoming launches of two FDA-approved products: Arbli™ (losartan potassium) oral suspension and Rezenopy® (naloxone HCl) nasal spray.
Scienture Holdings (NASDAQ: SCNX) has announced a strategic financial move following the FDA approval of Arbli™, their novel liquid losartan formulation. The company has drawn from its Equity Line of Credit (ELOC) to support Arbli's commercial launch while simultaneously suspending further ELOC draws for either 30 trading days or until the stock reaches $10 per share.
Arbli™, the first FDA-approved ready-to-use oral liquid losartan in the U.S. market, is indicated for treating hypertension in patients over 6 years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in certain type 2 diabetes patients. The commercial launch is expected in Q3 2025.
Scienture Holdings (NASDAQ: SCNX) has received FDA approval for ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL, the first and only FDA-approved ready-to-use oral liquid losartan in the U.S. market. The product is indicated for treating hypertension in patients over 6 years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in certain type 2 diabetes patients.
ArbliTM features two USPTO-issued patents and addresses the need for a liquid formulation, eliminating risks associated with crushing tablets. The product offers reduced dosing volume and long-term shelf life at room temperature storage. According to IQVIA data (MAT December 2024), the U.S. losartan market represents approximately $292 million in annual sales with 68 million prescriptions. The company plans to launch ArbliTM in Q3 2025.
Scienture Holdings (NASDAQ: SCNX) has announced a definitive agreement with Summit Biosciences (subsidiary of Kindeva Drug Delivery) for the exclusive U.S. rights to commercially launch REZENOPY®, a 10mg naloxone HCl nasal spray for opioid overdose treatment. The FDA-approved product represents the highest-strength naloxone HCl available in the market.
Under the agreement, Kindeva will manufacture and supply REZENOPY®, while Scienture will own the new drug application (NDA) and handle U.S. sales, marketing, and distribution. The product aims to combat the rising opioid-related fatalities through enhanced potency against powerful opioids.
According to IQVIA data (MAT December 2024), the US naloxone market shows annual sales of $189 million with a unit volume of 10.0 million. The collaboration aligns with Scienture's mission to provide innovative treatment solutions and expand patient access across therapeutic areas.
Scienture Holdings (NASDAQ: SCNX) announced that Dr. Narasimhan Mani, President of Scienture, will participate as an invited speaker and panelist at the 8th Annual Conference of The Society for the Study of Xenobiotics (SSX) in India. The conference is scheduled for January 23-25, 2025, at BITS Pilani, Hyderabad Campus.
Dr. Mani will present on the specialty pharmaceutical industry, focusing on technology-driven product innovations and efficient market strategies for improving patient access to novel therapies. He will also participate in panel discussions about global pharmaceutical industry trends, portfolio development, breakthrough technology platforms, and commercialization strategies.
Scienture Holdings (NASDAQ: SCNX), a specialty pharma company focused on novel brand products, has announced its upcoming participation in The Microcap Conference 2025. The event will be held from January 28-30, 2025, at the Borgata Hotel Spa & Casino in Atlantic City, NJ. The company's management team will present their corporate strategy and conduct one-on-one meetings with institutional and individual investors to discuss recent developments, growth plans, and investment opportunities.
Scienture (NASDAQ: SCNX) announced that the U.S. Patent and Trademark Office has issued a new patent (No. 12,156,869) for its product SCN-102, a Losartan Potassium Oral Suspension. This patent, along with the previously granted patent No. 11,890,273, covers stable liquid pharmaceutical compositions of Losartan and treatment methods. Both patents extend protection through 2041.
The company's SCN-102 product, currently under FDA review, aims to provide a ready-to-use oral liquid formulation of Losartan, one of the most widely prescribed molecules in its class. The patents demonstrate Scienture's development capabilities and commitment to addressing underserved patient needs.
Scienture Holdings (NASDAQ: SCNX) has secured two strategic financing arrangements: a private placement of 10% secured convertible debentures worth up to $12.22 million to be issued in three tranches to Arena Investors affiliates, and a $50 million equity line of credit (ELOC) agreement with Arena Business Solutions. The first tranche of approximately $3.33 million in debentures was completed on November 25, 2024. Dawson James Securities served as the sole placement agent. The ELOC allows Scienture to issue and sell up to $50 million in common stock over 36 months, though the company has no immediate plans to utilize it. Proceeds will support working capital and general corporate purposes.
TRxADE Health, Inc. has changed its name to Scienture Holdings, Inc. and its ticker symbol to "SCNX", effective September 23, 2024. The company will continue to trade on the Nasdaq Stock Market. Scienture Holdings, Inc., through its wholly owned subsidiaries Scienture and Integra Pharma Solutions, , is a comprehensive pharmaceutical product company focused on providing novel specialty products to meet unmet market needs.
The company's products are in development across various therapeutic areas and indications, catering to different market segments and channels. The executive team and board of directors consist of experienced industry veterans, including Suren Ajjarapu as CEO and Chairman, Prashant Patel as President, Interim CFO and COO, and other accomplished members.
FAQ
What is the current stock price of Scienture Holdings (SCNX)?
What is the market cap of Scienture Holdings (SCNX)?
